Suzanne Morris, DVM, MWC

Melissa Johnson, MD, discussed SHP2 inhibitors with Targeted Therapies in Oncology.

Wenxin (Vincent) Xu, MD, provides insight on biomarkers in renal cell carcinoma.

As we identify more targets...there will probably be more and newer, perhaps even better, therapeutics than we have currently, said Dennis J. Slamon, MD.